Skip to main content
Log in

An investigation of the mouse as a model for vincristine toxicity

  • Original Articles
  • Mouse Model Vincristine Toxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The purpose of this study was to investigate the toxicologic responses of mice to vincristine (VCR), an established antitumor drug, and to compare them with those reported for dogs, monkeys, and humans. This comparison was expected to facilitate the continuing appraisal of the mouse as a model for toxicologic responses to antitumor drugs in human patients. In duplicate experiments, male B6D2F1 mice were treated with 1.0, 1.5, 2.0, and 3.0 mg/kg of VCR in single IP doses. These sublethal doses corresponded to 0.25, 0.40, 0.50, and 0.80 LD50. On posttreatment days 1, 3, 6, 10, 14, and 21, groups of mice were killed and blood and other tissues were collected for hematologic (8 tests), clinical chemical (15 tests), and histopathologic (11 tissues) evaluations. VCR produced dose-dependent body weight loss, reticulocytopenia, granulocytopenia, elevated plasma alkaline phosphatase, GPT, and GOT activities, and damage to the gastrointestinal epithelium. These reversible changes were most severe during the first 3 days posttreatment. The mouse was comparable to the dog and the monkey in reflecting the target organ toxicity of VCR in humans. Studies with additional antitumor drugs will be required before the overall predictive reliability of this model can be expressed quantitatively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Adamson RH, Dixon RL, Ben M, Crews L, Shohet SB, Rall DP (1965) Some pharmacologic properties of vincristine. Arch Int Pharmacodyn 157: 299

    Google Scholar 

  2. Cancer Letter (1979) Editorial. 5

  3. Cancer Letter (1982) Editorial. 4

  4. Carpentieri U, Lockart LH (1978) Ataxia and athetosis as side effects of chemotherapy with vincristine in non-Hodgkin's lymphoma. Cancer Treat Rep 62: 561

    Google Scholar 

  5. Costa G, Hreshchyshyn MM, Holland JF (1962) Initial clinical studies with vinristine. Cancer Chemother Rep 24: 39

    Google Scholar 

  6. Folk RM, Peters AC, Pavkov KL, Swenberg JA (1974) Vincristine (NSC-67574): a retrospective toxicologic evaluation in monkeys and dogs using weekly intravenous injections for 6 weeks. Cancer Chemother Rep 5: 17

    Google Scholar 

  7. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219

    Google Scholar 

  8. Harrison SD Jr (1981) Toxicologic evaluation of cis-diamminedichloroplatinum II in B6D2F1 mice. Fundamentals of Applied Toxicology 1: 382

    Google Scholar 

  9. Harrison SD Jr (1982) Variable host response to cytotoxic drugs: lethality, lesions and lessons. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, p 136

    Google Scholar 

  10. Harrison SD Jr, Burdeshaw JA, Crosby RG, Cusic AM, Denine EP (1978) Hematology and clinical chemistry reference values for C57BL/6 x DBA/2F1 mice. Cancer Res 38: 2636

    Google Scholar 

  11. Harrison SD JR, Giles HD, Denine EP (1980) Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother Pharmacol 4: 199

    Google Scholar 

  12. Prieur DJ, Young DM, Davis RD, Cooney DA, Homan ER, Dixon RL, Guarino AM (1973) Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the Laboratory of Toxicology. Cancer Chemother Rep 4: 1

    Google Scholar 

  13. Sethi VS, Kimball JC (1981) Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 6: 111

    Google Scholar 

  14. Sethi VS, Jackson DV Jr, White DR, Richards F II, Stuart JJ, Muss HB, Cooper MR, Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41: 3551

    Google Scholar 

  15. Smart CR, Ottoman RE, Rochlin DB, Hornes J, Silva AR, Goepfert H (1968) Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases. Cancer Chemother Rep 52: 733

    Google Scholar 

  16. Uy QL, Moen TH, Johns RJ, Owens AH Jr (1967) Vincristine neurotoxicity in rodents. Johns Hopkins Med J 121: 349

    Google Scholar 

  17. Weber W, Nagel GA, Nagel-Studer E, Albrecht R (1979) Vincristine infusion. A phase I study. Cancer Chemother Pharmacol 3: 49

    Google Scholar 

  18. Whitelaw DM, Cowan DH, Cassidy FR, Patterson TA (1963) Clinical experience with vincristine. Cancer Chemother Rep 30: 13

    Google Scholar 

  19. Wolf PL (1978) Clinical significance of an increased or decreased serum alkaline phosphatase level. Arch Pathol Lab Med 102: 497

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, S.D. An investigation of the mouse as a model for vincristine toxicity. Cancer Chemother. Pharmacol. 11, 62–65 (1983). https://doi.org/10.1007/BF00257421

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257421

Keywords

Navigation